1	Differential Causal Effects of Type 1 and Type 2 Diabetes on Osteomyelitis Risk:
2	Insights from Mendelian Randomization Analysis
3	YanHui Li <sup>1</sup> , MD; Chuanyang Zhou <sup>2</sup> , MD; Liming Yang <sup>3</sup> , MD; Lei Tan <sup>2</sup> , MD
4	<sup>1</sup> Department of Cardiology and Echocardiography, Ultrasound Diagnostic Center,
5	the First Hospital of Jilin University, Changchun, 130021, China
6	<sup>2</sup> Department of OrthopedicsTrauma, Orthopaedic Center, the First Hospital of
7	Jilin University, Changchun, 130021, China
8	<sup>3</sup> Department of Cardiac Surgery, the First Hospital of Jilin University,
9	Changchun, 130021, China
10	
11	Running title: Causal Effects of Diabetes on Osteomyelitis Risk
12	Author for correspondence:
13	Lei Tan, MD
14	Department of Orthopedic Trauma, Orthopaedic Center, The First Hospital of
15	Jilin University; No. 71 Xinmin Street, Changchun, Jilin, China; tanlei@jlu.edu.cn
16	E-mail addresses:
17	YanHui Li: yan_hui@jlu.edu.cn
18	Chuanyang Zhou: cyzhou22@mails.jlu.edu.cn
19	Liming Yang: yanglmjdyy@jlu.edu.cn
20	Lei Tan: tanlei@jlu.edu.cn
21	

## **Abstract:**

1 2

Background: Osteomyelitis (OM) poses a significant clinical challenge, especially among individuals with diabetes mellitus (DM). While both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) have been linked to an elevated risk of OM, the precise causal relationships remain uncertain.

7

9

10

11

12

13

14

Methods: We conducted Mendelian randomization (MR) analyses using summary statistics from genome-wide association studies (GWAS) to explore the causal effects of T1DM, T2DM, their complications, and glycemic traits on OM risk. The study utilized the inverse variance weighted (IVW) method, along with weighted median and MR-Egger for causal estimation, and performed various sensitivity analyses to ensure robustness. Multivariable MR (MVMR) analysis assessed direct effects, while two-step mediation MR analyses investigated the mediating role of DM between rheumatoid arthritis (RA) and OM.

1516

17 Results: The MR analysis unveiled distinct causal effects of T1DM and T2DM on 18 OM risk. Genetically determined T2DM, rather than its complications, significantly 19 increased OM risk (primary dataset: IVW: OR = 1.13, 95% CI 1.056-1.209, p = 20 4E-04; validation dataset: IVW: OR = 1.317, 95% CI 1.14-1.522, p = 2E-04; 21 Meta-analysis: OR=1.206; 95% CI 1.037–1.402; p=0.014), with no observable 22 heterogeneity or horizontal pleiotropy. MVMR analysis confirmed the robustness of 23 the causal association between T2DM and OM, even after adjusting for potential 24 confounders such as body mass index. Conversely, T1DM and its complications 25 showed no significant causal link with OM in either the primary dataset (IVW: p =26 0.071), the validation dataset (IVW: p = 0.276), or the meta-analysis (IVW: p = 0.242). 27 Additionally, there was no robust evidence supporting the causal risk of glycemic 28 traits on OM. Mediation MR analysis underscored T2DM as a pivotal contributor to 29 the differential effects of RA on OM.

30 31

32

33

34

35

36

Conclusions: Mendelian randomization analysis provides compelling evidence of a significant causal relationship between genetically determined T2DM and increased OM risk, while T1DM exhibits distinct causal effects. Additionally, our findings highlight the role of T2DM in mediating the association between RA and OM. Further research is warranted to elucidate the underlying mechanisms and guide targeted interventions for OM prevention and management in diabetic populations.

3738

39

# Introduction

40 Osteomyelitis (OM), a bone infection, can occur via contiguous spread from

surrounding tissues, direct bone trauma, or hematogenous dissemination. It poses a considerable healthcare burden, with a prevalence of 22 cases per 100,000 person-years in the United States, rising over time, especially among the elderly and those with diabetes mellitus (DM)<sup>1</sup>. Challenges in treatment include pathogen identification, bone destruction and repair complexities, and disease recurrence, resulting in prolonged treatment and poorer prognoses<sup>2</sup>.

Diabetes mellitus, affecting nearly 500 million individuals worldwide and projected to increase by 51% by 2045, poses a significant global health challenge<sup>3</sup>. Type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are the primary forms, each with distinct pathophysiological mechanisms. While T1DM stems from autoimmune destruction of pancreatic beta cells, T2DM involves insulin resistance and impaired insulin secretion<sup>4</sup>. Although observational studies have linked DM to a higher risk of OM<sup>5,6</sup>, uncertainties persist regarding causal relationships and potential mediators due to confounding factors and biases in existing research. Moreover, limited studies have explored the differing impacts of diabetes subtypes on OM risk.

Clinical studies have established a link between Rheumatoid Arthritis (RA) and heightened susceptibility to OM, attributed to chronic inflammation<sup>7,8</sup>. RA is also associated with diabetes due to a vicious circle perpetuated by glucose derangement and inflammatory mediators.<sup>9,10</sup>. Given the shared risk profile of RA with both diabetes and OM, we employed mediation MR analysis to investigate the mediating role of DM between RA and OM.

 Randomized controlled trials (RCTs) are ideal for understanding causality, but their implementation is impractical due to ethical and complex relations between OM and diabetes. MR offers an alternative using genetic variation as a proxy for exposure, mitigating bias<sup>11</sup>. This method mirrors RCTs, validating causal relationships while reducing biases. Moreover, MR elucidates independent causal pathways and potential mediators linking DM and OM.

In this study, we utilized univariable MR (UVMR) analyses to evaluate the impact of T1DM, T2DM, and their complications on OM risk, as well as to explore the association between glycemic traits and OM. Multivariable MR (MVMR) analysis was conducted to assess direct effects by adjusting for potential confounders. Additionally, two-step mediation MR analyses were employed to explore DM's mediating role between RA, and OM.

# Methods

1. Study design and data sources

1 In this study, we employed UVMR, UVMR and two-step mediation MR analyses to 2 examine the causal effects of T1DM, T2DM, their complications and glycemic traits 3 on OM risk, and to explore DM's mediating role between RA and OM. Throughout 4 the study, we rigorously adhered to three core assumptions ensured the validity of our 5 results: (1) establishing a reliable association between genetic variants and the risk 6 factor; (2) confirming no association between genetic variants and confounders; and 7 (3) ensuring genetic variants solely influence the outcome through the risk factors. A 8 comprehensive study design flowchart is provided in Figure 1. 9 Our study utilized the largest and most recent publicly available summary statistics 10 from multiple genome-wide association studies (GWAS) sources, including the 11 FinnGen database, the UK Biobank (UKBB) database, and other large consortia. To 12 prevent overlap, we carefully selected exposure factors, designating T1DM and 13 T2DM data from FinnGen, and OM data from the UKBB as the primary dataset. DM 14 data from non-FinnGen sources and additional data from FinnGen were designated as 15 the validation dataset. To ensure robustness, we conducted a meta-analysis of results from these datasets. Adherence to the STROBE-MR (Strengthening the Reporting of 16 Mendelian Randomization Studies) guidelines was maintained throughout the study<sup>12</sup>. 17 18 Detailed information on the GWAS data used in this study is provided in 19 Supplementary Tables 1.

20

21 22

23

24

25

26




Figure 1. Flowchart of the study design. GWAS, genome-wide association studies; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; RA, rheumatoid arthritis; OM, osteomyelitis; UVMR, Univariable MR; MVMR, multivariable mendelian randomization; BMI, body mass index; UKBB, United Kingdom Biobank; IVs, instrument variables.

- 1 2. Genetic association datasets
- 2 GWAS data for T1DM and T1DM with complications
- 3 Type 1 Diabetes (T1DM) genetic instruments were selected from two GWAS Studies.
- 4 THE Non-UKBB One is based on 5,928 cases and 183,185 controls of European
- 5 ancestry from the FinnGen database as the primary source. Validation (Non-FinnGen)
- 6 was conducted meta-analysis using data from Onengut-Gumuscu et al.'s study, which
- 7 included 6,683 T1DM cases from the UK Genetic Resource Investigating Diabetes
- 8 cohort and control samples (N=12,173) from four additional cohorts, all reporting
- 9 European ancestry<sup>13</sup>. T1DM with complications dataset obtained from FinnGen
- database<sup>14</sup>.Detailed information on single nucleotide polymorphisms (SNPs) used in
- this study is presented in Supplementary Tables S4 and S6.

- 13 GWAS data for T2DM and T2DM with complications
- 14 The genetic instruments for T2DM were derived from FinnGen database comprising
- 15 32,469 cases and 183,185 controls of European ancestry as the primary source
- 16 (Non-UKBB). For validation (Non-FinnGen), we utilized data from the GWAS
- meta-analysis study by Xue A et al., which included a sample of 61,714 cases and
- 18 593,952 controls with T2DM. This study combined three GWAS datasets of European
- ancestry, including UKBB, representing the vast majority (99.4%) of individuals of
- 20 European ancestry<sup>15</sup>. T2DM with complications dataset obtained from FinnGen
- 21 database<sup>14</sup>. Detailed information regarding the SNPs used can be found in
- 22 Supplementary Tables S6 and S10.

23

- 24 GWAS data for Hyperglycemia traits
- 25 SNPs were chosen from a GWAS meta-analysis by Chen et al., involving 151,013
- 26 European individuals for fasting insulin, up to 200,622 participants for fasting glucose
- 27 <sup>16</sup>. The GWAS summary statistics for HbA1c levels were obtained from Within family
- 28 GWAS consortium, which included 45,734 participants of European ancestry. All
- 29 participants had European ancestry, and there was no overlap with the outcome data.
- 30 Detailed SNP information is available in Supplementary Tables S12, 14 and 16.

31

- 32 GWAS data for Body mass index (BMI)
- 33 The GWAS summary statistics for MVMR (BMI) were sourced from Within family
- 34 GWAS consortium, involving 99,998 European participants. There was no overlap
- 35 between this dataset and other exposures and outcomes considered in our study.

- 37 GWAS data for RA
- 38 The GWAS summary statistics for RA were obtained from Eyre S et al., which
- 39 included 13,838 cases and 33,742 controls of European ancestry<sup>17</sup>. There was no
- 40 overlap between this dataset and all exposures and outcomes considered in our study.

1 Supplementary Table 18 provides details of the traits involved in this analysis.

2

- 3 GWAS data for Outcomes
- 4 The study outcome is OM, defined as inflammation of bone and its structures due to
- 5 pyogenic bacterial infection. We analyzed the associations between selected
- 6 instruments and OM using summary GWAS data from the UK Biobank (4,836 cases,
- 7 481,648 controls) as the primary source. Validation was performed using FinnGen
- 8 data (842 cases, 209,575 controls), all of European ancestry.

9

- 10 3.Genetic Instrument Selection
- 11 For genetic instrument selection, we established a genome-wide significance
- 12 threshold. SNPs with a P-value less than  $5\times10^{-8}$  were considered significant for
- 13 T1DM, T2DM, glycemic traits, BMI and RA. Since only few SNPs were identified
- 14 for part of complications of DM when they were as the exposure, a higher cutoff
- 15 (p□<□1e-6) was chosen. Variants meeting these criteria were then clumped for
- linkage disequilibrium (LD) using a distance window of 10,000 kB and an  $r^2 < 0.01$ .
- 17 To avoid the risk of weak instrumental bias, the F statistic was performed to evaluate
- 18 the strength of the IV. When  $F \square > \square 10$ , the association between the IV and exposures
- was deemed to be sufficiently robust, thereby safeguarding the results of the MR
- 20 analysis against potential weak instrumental bias. The PhenoScanner
- 21 (http://www.phenoscanner.medschl.cam.ac.uk/) was introduced to identify and
- 22 remove SNPs with potential associations with confounding factors that might violate
- 23 the independence assumption<sup>18</sup>. After several rounds of rigorous filtering, a set of
- 24 eligible instrumental variables for the subsequent MR analysis were obtained.
- 25 Summary of the instrument variables used in this study is presented in Supplementary
- Tables S2.

27

- 4. Statistical analysis
- 29 We employed the "TwoSampleMR" 22, "MendelianRandomization" 23 and
- 30 "MR-PRESSO"24 packages for UVMR, MVMR, and Mediation MR analyses,
- 31 including sensitivity tests. Causal estimates were expressed as odds ratios (ORs) with
- 32 95% confidence intervals (CIs). Statistical analyses were conducted using R software
- version 4.3.2 (The R Foundation for Statistical Computing).

- 35 UVMR analysis
- 36 Causal effects were estimated using the random-effects inverse variance weighted
- 37 (IVW) method <sup>19</sup>. To ensure unbiased estimates, MR analyses were also conducted
- 38 using four alternative methods (MR Egger, Simple mode, Weighted median, and
- 39 Weighted mode). A causal effect was considered suggested if the IVW p-value was

- less than 0.05. Moreover, a causal effect was deemed significant if the IVW p-value
- fell below the Bonferroni-corrected threshold ( $(p \square < \square 0.05/21 \square = \square 0.002)$ ) for primary
- datasets and (p $\square$ < $\square$ 0.05/7 $\square$ = $\square$ 0.007) for validation datasets, coupled with consistent
- 4 directionality in the weighted median and MR-Egger results.

- 6 MVMR
- 7 The DM and BMI shared genetic risk factors<sup>20</sup>. To mitigate the confounding influence
- 8 of BMI on DM, MVMR analysis adjusting for BMI was performed. For the
- 9 significant causal associations in the univariable MR analysis, the MVMR analysis
- 10 was performed using the MVMR-IVW method, aiming to adjust for potential
- 11 confounding factors BMI<sup>21</sup>.

12

- 13 Mediation MR analysis
- 14 Clinical studies indicate that RA is associated with an increased risk of OM<sup>9</sup>. To
- 15 explore whether DM mediates this association, we conducted two-step mediation MR
- analysis, assessing three key estimates: (i) the total effect of RA on OM ( $\beta$ \_all); (ii)
- the direct effect of RA on DM ( $\beta$ 1); and (iii) the direct effect of DM on OM ( $\beta$ 2).
- 18 Significance was determined by IVW p-values ( $p \square < \square 0.05$ ), with mediation effect
- proportions estimated using the delta method. The mediation effect is calculated as  $\beta 1$
- 20 \* β2. The proportion of the mediation effect was estimated as the total causal effect of
- $\beta$ \_all divided by the mediation effect. We performed two-step mediation MR analyses
- 22 in both primary and validation datasets to ensure result reliability and compared them
- 23 for consistency.

2425

- Sensitivity analyses
- 26 Sensitivity analyses were performed to address horizontal pleiotropy and
- 27 heterogeneity. We utilized weighted median, MR-Egger, and MR-PRESSO methods
- 28 to verify assumptions and assess robustness, identifying potential horizontal
- 29 pleiotropy. The weighted median model provides consistent estimates when over half
- 30 of the weights are from valid IVs<sup>25</sup>. MR-Egger regression detects horizontal
- 31 pleiotropy and corrects for it, with its intercept term indicating unbalanced directional
- 32 pleiotropy  $(p < 0.05)^{26}$ . MR-PRESSO identifies and corrects outliers, providing
- 33 outlier-corrected estimates. The MR-PRESSO distortion test compares estimation
- 34 differences before and after outlier removal. Cochran's Q test evaluates heterogeneity
- 35 among SNPs for exposure and confirms consistency between MR assumptions and
- analyses  $(p < 0.05)^{24}$ . Credible causal inference requires consistent directionality
- across the three methods and the absence of horizontal pleiotropic effects.

- Results
- 40 1.NO Causal effects of T1DM on OM

1 The causal effect of T1DM on OM was not supported in either the primary dataset 2 (IVW: p = 0.071), the validation dataset (IVW: p = 0.276), or the meta-analysis (IVW: 3 p = 0.242). Sensitivity analyses revealed consistent results with no evidence of 4 horizontal pleiotropy (MR-Egger intercept p = 0.521; p = 0.967) and no heterogeneity 5 (Cochran's Q statistic: p = 0.089; p = 0.244) for the primary and validation datasets, 6 respectively. No outliers were found in the MR-PRESSO test. To further address the 7 potential influence of confounding factors and level pleiotropy, we conducted MVMR. 8 After controlling for BMI, no statistical significance remained between T1DM and 9 OM (Figure 2; Supplementary Table S3). Leave-one-out and scatter plots are provided 10 in Supplementary Figures 1-4. 11 To explore the relationship between different T1DM subgroups and OM, we analyzed 12 data from the comprehensive FinnGen database, known for its coverage of T1DM 13 complications. Our analysis revealed no causal correlations between either T1DM 14 without complications or T1DM with complications and OM (IVW: p = 0.478; 15  $p \square = \square 0.777$ , respectively). Further subgroup analyses within T1DM with 16 complications showed no causal links with OM. Specifically, IVW -P values for OM 17 were 0.885 for T1DM with coma, 0.843 for T1DM with ketoacidosis, 0.770 for 18 T1DM with ophthalmic complications, 0.978 for T1DM with renal complications, 19 0.197 for T1DM with peripheral circulatory complications, and 0.345 for T1DM with 20 neurological complications. No evidence of horizontal pleiotropy or heterogeneity

was found in these MR analyses. (Figure 2; Supplementary Table S5).

Exposure	Outcome	nsnp	method		OR(95% CI)	pval	MVMR_pval	H_pval	P_pv
T1DM(FinnGen)	OM(UKBB)	58	IVW	P	1.031 (0.997 to 1.066)	0.071	0.302	0.089	
			MR Egger	•	1.046 (0.991 to 1.105)	0.127			0.521
			Weighted median		1.044 (1.008 to 1.082)	0.016			
T1DM	OM(FinnGen)	36	IVW	<b>⊢</b>	1.054 (0.959 to 1.159)	0.276	0.144	0.244	
			MR Egger	<b>→</b>	1.051 (0.885 to 1.248)	0.575			0.967
			Weighted median	<b>→</b>	1.008 (0.866 to 1.174)	0.916			
Meta									
T1DM	ОМ		IVW	<del></del>	1.153 (0.908 to 1.465)	0.242			
			MR Egger	<del></del>	1.166 (0.871 to 1.559)	0.302			
			Weighted median	-	1.193 (0.881 to 1.615)	0.253			
T1DM without	OM(UKBB)	15	IVW	•	0.983 (0.937 to 1.031)	0.487	0.43	0.161	
complications			MR Egger	H <del>i</del> H	0.988 (0.896 to 1.090)	0.815			0.90
			Weighted median	· ·	1.012 (0.953 to 1.075)	0.697			
T1DM with									
multiple	OM(UKBB)	15	IVW	•	1.004 (0.975 to 1.035)	0.777	0.734	0.242	
complications			MR Egger	•	1.013 (0.968 to 1.059)	0.594			0.63
			Weighted median	•	1.017 (0.982 to 1.053)	0.352			
coma	OM(UKBB)	9	IVW	•	1.002 (0.973 to 1.032)	0.885	0.849	0.155	
			MR Egger	•	1.013 (0.964 to 1.065)	0.626			0.60
			Weighted median	•	1.012 (0.982 to 1.043)	0.450			
ketoacidosis	OM(UKBB)	10	IVW		1.003 (0.972 to 1.035)	0.843	0.772	0.063	
			MR Egger	ė.	1.017 (0.969 to 1.068)	0.517			0.48
			Weighted median	•	1.011 (0.982 to 1.042)	0.450			
ophthalmic	OM(UKBB)	16	IVW	÷	0.995 (0.959 to 1.031)	0.770	0.995	0.069	
complications			MR Egger	•	1.028 (0.973 to 1.086)	0.340			0.14
			Weighted median	•	1.002 (0.964 to 1.042)	0.903			
enal complication	OM(UKBB)	7	IVW	•	1.000 (0.971 to 1.031)	0.978	0.801	0.238	
			MR Egger	•	1.030 (0.992 to 1.069)	0.182			0.08
			Weighted median	•	1.013 (0.983 to 1.045)	0.404			
peripheral	OM(UKBB)	3	IVW	•	1.018 (0.991 to 1.045)	0.197	0.177	0.58	
circulatory			MR Egger	H <del>P</del> H	1.020 (0.937 to 1.111)	0.725			0.96
complications			Weighted median	•	1.017 (0.989 to 1.047)	0.237			
neurological	OM(UKBB)	9	IVW	ģi.	1.016 (0.983 to 1.051)	0.345	0.424	0.35	
complications			MR Egger	÷+	1.049 (0.969 to 1.136)	0.275			0.41
			Weighted median		1.035 (0.993 to 1.078)	0.107			

- 1 Figure. 2.Genetically predicted type 1 diabetes and its complications: associations
- with osteomyelitis. T1DM, type 1 diabetes mellitus; OM, osteomyelitis; UVMR,
- 3 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,
- 4 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
- 5 Weighted; H, Heterogeneity; P, Pleiotropy. p-values (IVW) □<□0.05 was considered
- 6 suggested different. The Bonferroni-corrected results of the p-values (IVW) in each
- 7 group remained consistent with the uncorrected results.

- 9 2. Causal effects of T2DM on OM
- 10 Using IVs for T2DM, we found evidence linking genetically predicted T2DM to
- increased OM risk (primary dataset: IVW: OR = 1.13, 95% CI 1.056–1.209, p =
- 12 4.20E-04; validation dataset: IVW: OR = 1.317, 95% CI 1.14–1.522, p = 0.007;
- 13 Meta-analysis: OR 1.203; 95% CI 1.038–1.395; p=1.85E-04) (Figure 2). Furthermore,
- 14 after Bonferroni correction, the results remained statistically significant. The three
- 15 MR methods showed consistent directions. After MVMR analysis controlling for BMI,
- statistical significance remained between T2DM and OM (Figure 3; Supplementary
- 17 Table S7). No outliers were detected by MR-PRESSO, and no heterogeneity was
- 18 observed by Cochran's Q test. MR-Egger intercept tests found no horizontal
- 19 pleiotropy. Leave-one-out analysis showed consistent T2DM results (Fig. 2).
- 20 Leave-one-out and scatter plots are provided in Supplementary Figures 5-8.
- 21 Using GWAS data for T2DM complications from the FinnGen database, we initially
- 22 observed suggested causal correlations between both T2DM without complications
- 23 and T2DM with multiple complications and OM (IVW: OR 1.128; 95% CI
- 24 1.033–1.232;  $p \square = \square 0.008$ ; OR 1.086; 95% CI 1.109–1.158;  $p \square = \square 0.011$ ),
- 25 respectively. However, after multiple testing correction, these causal correlations
- disappeared. Furthermore, analyses for T2DM with other complications revealed no
- 27 significant causal correlations with OM. Specifically, IVW-P values for OM were
- 28 0.164 for T2DM with coma, 0.349 for T2DM with ketoacidosis, 0.215 for T2DM with
- 29 ophthalmic complications, and 0.053 for T2DM with peripheral circulatory
- 30 complications. These MR analyses showed no evidence of horizontal pleiotropy or
- 31 heterogeneity (Figure 3; Supplementary Table S9). Insufficient genetic instruments
- were available for MR analyses of other T2DM-related complications.

- 34 The findings suggest that genetically predicted T2DM, rather than T2DM with
- 35 complications, is a risk factor for OM.

Exposure	Outcome	nsnp	method		OR(95% CI)	pval	MVMR_pval	H_pval	P_pva
2DM(FinnGen)	OM(UKBB)	58	IVW	HeH.	1.130 (1.056 to 1.209)	4e-04	5e-04	0.969	
			MR Egger	<del>i</del> •••	1.118 (0.966 to 1.293)	0.14			0.87
			Weighted median	<del>-</del>	1.059 (0.947 to 1.184)	0.314			
T2DM	OM(FinnGen)	114	IVW		1.317 (1.140 to 1.522)	2e-04	9e-04	0.738	
			MR Egger	<u> </u>	1.429 (1.014 to 2.014)	0.044			0.609
			Weighted median		1.427 (1.125 to 1.811)	0.003			
Meta									
T2DM	OM		IVW		1.203 (1.038 to 1.395)	0.014			
			MR Egger	<u> </u>	1.201 (0.965 to 1.495)	0.101			
			Weighted median	<del>-</del>	1.206 (0.902 to 1.612)	0.206			
Γ2DM without	OM(UKBB)	21	IVW	н	1.128 (1.033 to 1.232)	0.008	0.027	0.969	
complications			MR Egger	<u> </u>	1.046 (0.842 to 1.300)	0.659			0.464
			Weighted median	<del>-</del>	1.093 (0.963 to 1.241)	0.17			
T2DM with									
multiple	OM(UKBB)	56	IVW	þен	1.086 (1.019 to 1.158)	0.011	0.017	0.755	
complications			MR Egger	<del></del>	1.095 (0.951 to 1.260)	0.212			0.9
			Weighted median	н-	1.046 (0.934 to 1.170)	0.438			
coma	OM(UKBB)	6	IVW	<del>ļo</del> +	1.058 (0.977 to 1.147)	0.164	0.212	0.433	
			MR Egger	<del></del>	1.053 (0.844 to 1.314)	0.67			0.965
			Weighted median	<del>-io-</del> i	1.049 (0.949 to 1.160)	0.349			
ketoacidosis	OM(UKBB)	5	IVW	•	1.002 (0.973 to 1.032)	0.881	0.649	0.288	
			MR Egger	•	1.000 (0.955 to 1.046)	0.991			0.884
			Weighted median	•	0.995 (0.960 to 1.031)	0.786			
ophthalmic	OM(UKBB)	6	IVW	<b>6</b> 14	1.038 (0.979 to 1.100)	0.215	0.469	0.937	
complications			MR Egger	-	1.033 (0.918 to 1.163)	0.617			0.939
			Weighted median	io-i	1.049 (0.978 to 1.125)	0.182			
peripheral	OM(UKBB)	7	IVW	101	1.048 (0.999 to 1.098)	0.053	0.374	0.981	
circulatory			MR Egger	<b></b>	1.057 (0.978 to 1.141)	0.219			0.789
complications			Weighted median	( <b>0</b> 4	1.045 (0.982 to 1.111)	0.169			

Figure. 3.Genetically predicted type 2 diabetes and its complications: associations with osteomyelitis. T2DM, type 2 diabetes mellitus; OM, osteomyelitis; UVMR, Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI, confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance Weighted; H, Heterogeneity; P, Pleiotropy. The IVW p-value (<□0.05) was considered a statistically suggested difference. IVW p-values below the Bonferroni-corrected threshold were considered statistically significant.

1 2

# 3. Inconsistent Causal Effects of Glycemic Traits on OM

There was no causal relationship between fasting insulin and OM in either the primary dataset (IVW: p=0.566) or the validation dataset (IVW: p=0.463). However, fasting glucose showed inconsistent effects on OM. In the primary dataset, the IVW analysis yielded a p-value greater than the threshold (IVW: OR = 1.265, 95% CI: 0.972-1.645, p=0.08), while in the validation dataset, the p-value was smaller than the Bonferroni-corrected threshold (IVW: OR = 2.347, 95% CI: 1.276-4.318, p=0.006). However, meta-analysis did not support fasting glucose as a risk factor for OM (IVW: p=0.11). Similarly, inconsistent results were observed for HbA1c levels and OM in the primary dataset (p=0.29) and the validation dataset (IVW: p=0.04), with the latter failing the Bonferroni correction for multiple testing. Nevertheless, meta-analysis indicated that HbA1c levels were not associated with an increased risk of OM (IVW: p=0.59). Sensitivity analyses confirmed no evidence of heterogeneity or horizontal pleiotropy (Table 1, Supplementary Tables S11, S13 and S15). These findings suggest that there may be complex relationships between glycemic traits and OM.

E	OM(UKBB)										Meta							
Exposure	Met hod	nsnp	bet a	se	pval	M/MR p	H_pval	P- pval	nsnp	beta	se	pval	MMR-p	H_pval	P- pval	bet a	se	Pval
Fasting insulin	IW	38	0.14	0. 24	0. 57	0.50	0.92	0.74	38	0.43	0.59	0.46	0.45	0.44	0. 524	0.18	0.22	0. 42
	MR Egger		0.37	0.73	0.61					- 0. 73	1.90	0.70				0. 23	0.68	0.74
	Weighted median		0.21	0.33	0. 52					0.89	0.86	0.30				0.30	0.31	0.33
Fasting glucose	IW	63	0.24	0.13	0.08	0.08	0.67	0.76	63	0.85	0.31	6.10E-03	1. 20E-03	0.79	0.11	0.48	0.30	0.11
	MR Egger		0.17	0.24	0.49					1.60	0.56	5.86E-03				0.80	0.71	0.26
	Weighted median		0.27	0.20	0.17					1.02	0.48	0.04				0.52	0.35	0.14
-bA1c levels	l W	29	- 0. 06	0.06	0. 29	0.16	0.61	0.06	25	0.33	0.16	0.04	0. 11	0.80	0. 61	0.10	0.19	0.59
	MR Egger		- 0. 26	0.12	0.03					0.48	0.34	0.17				0.04	0.37	0.91
	Weighted median		- 0. 18	0.09	0.04					0.41	0.24	0.09				0.07	0.29	0.81

#### 2 4.T2DM mediates the causal effect of RA on OM

We employed two-step mediation MR analyses in both primary and validation datasets to explore T2DM's mediation between RA, and OM. RA was associated with increased OM risk (IVW: OR $\square$ = $\square$ 1.058, 95% CI 1.005–1.114,  $P\square$ = $\square$ 0.031), with a 25.8% mediation effect (95% CI 9.0%–42.5%) in the primary dataset. Consistent results were observed in the validation dataset analysis, with T2DM mediating 14.5% (95% CI 6.1%–23.0%) of the RA-OM relationship. No heterogeneity or horizontal pleiotropy was detected in any analysis (Table 2; Supplementary Table 17).

Exposure M				10	сат ептес	et β_all		Direct effe	ct ß1		Direct effect	β2	Mediatio	on effect			
	Mediator	Outcome	Dataset	beta	se	P	beta	se	P	beta	se	P	Effect size (95% CI)	Proportion % (95% CI)			
RA T2DM	T2DM	014	OM	OM		Primary	0.06	0.03	3.14E-02	0.12	0.02	4.91E-07	0.12	0.03	4.20E-04	0.014(0.005-0.024)	25.8(9.0-42.5)
KA .	1 2DW	OW	Validation	0.18	0.05	5.34E-04	0.09	0.01	7.67E-17	0.28	0.07	1.85E-04	0.026(0.011-0.041)	14.5(6.1-23.0)			
bbreviatio	on:MR,M	endel i an	Randomi za	tion;	T2DM t	ype 2 dia	betes n	nellitus;	OM osteomye	litis;	RA Rheumat o	id arthriti	is; CR, odds ratio.				

## Discussion

Our MR study revealed distinct causal effects of T1DM and T2DM on OM risk. Specifically, T2DM showed a significant association with increased OM risk, while T1DM and its complications did not exhibit a causal relationship with OM. Additionally, glycemic traits (fasting insulin, fasting glucose, and HbA1c) showed inconsistent effects on OM. Furthermore, we identified that T2DM mediates the causal effect of RA on OM. These findings deepen our understanding of the differing roles of T1DM and T2DM in OM development and provide avenues for further mechanistic investigation.

The discovery that that T1DM and its complications did not exhibit a causal association with OM challenges our conventional understanding and contradicts some previous study findings. <sup>27–29</sup>. Traditionally, diabetes, including both T1DM and T2DM, has been linked to an elevated risk of various infection complications, such as OM. Moreover, individuals with diabetes face a higher mortality risk from infections compared to the general population, with T1DM patients particularly susceptible<sup>30</sup>. However, our Mendelian randomization analysis, which provides more robust causal inference compared to observational studies, suggests otherwise. This unexpected

result prompts a reevaluation of the assumed causal relationship between T1DM and OM. One possible interpretation could involve the complex interplay between diabetes subtypes and their respective pathophysiological mechanisms. While T2DM is commonly associated with metabolic abnormalities and chronic inflammation, the etiology of T1DM involves autoimmune destruction of pancreatic beta cells. It is plausible that the mechanisms underlying T1DM may not directly contribute to the development of OM, as observed in our study. Another explanation for this discrepancy could be the differences in study design and inherent biases between observational studies and Mendelian randomization. Observational studies are limited to establishing associations and are susceptible to confounding factors, reverse causation, and measurement errors, which may lead to spurious associations. In contrast, Mendelian randomization leverages genetic variants as instrumental variables to mimic the random assignment of exposures, thereby reducing bias and providing more reliable causal estimates<sup>31</sup>.

The finding that T2DM is significantly associated with increased OM risk aligns with previous clinical studies<sup>1,5,6</sup>. However, our analysis reveals an unexpected causal relationship between glycemic traits and OM risk. The absence of associations with fasting insulin and HbA1c implies that insulin and HbA1c levels may not contribute to OM risk. Inconsistent causal effects of fasting glucose were observed between the primary dataset and validation dataset, and meta-analysis did not support fasting glucose as a risk factor for OM. Therefore, T2DM may influence OM risk through alternative mechanisms beyond high blood sugar, such as immune response dysfunction <sup>32</sup> or metabolic disturbances <sup>33</sup>. These findings emphasize the need for further research to elucidate the specific pathways through which T2DM affects OM risk. Additionally, they underscore the importance of comprehensive risk assessment in diabetic patients, beyond glycemic control alone.

Previous research has established RA as a common risk factor for both T2DM and OM<sup>7,9,10</sup>. Our study further investigated their associations with T2DM and OM risk, revealing the extent to which T2DM mediates RA's causal effect on OM. These findings underscore the importance of addressing RA to prevent OM and highlight T2DM's role in connecting RA with OM. Such insights have significant clinical implications, suggesting targeted interventions for diabetic patients with RA to mitigate their heightened susceptibility to OM, particularly those requiring orthopedic procedures like fracture fixation or joint replacement. Strategies focusing on optimizing glycemic control and managing inflammation in this patient population may help reduce the risk of OM.

40 Our study reveals distinct causal effects of T1DM and T2DM on OM risk,

underscoring the need for tailored disease management. Further validation is essential for a comprehensive understanding of these findings. The observed differences in OM risk between T1DM and T2DM warrant further investigation into underlying pathophysiological heterogeneity. Future research should focus on identifying biomarkers to stratify diabetic patients based on their susceptibility to OM and related complications. Additionally, our findings suggest potential drug repurposing for OM management among diabetic patients, emphasizing the importance of clinical trials to validate efficacy and safety profiles. While our study provides valuable insights, prospective clinical studies are needed to validate our findings and improve clinical outcomes for diabetic patients.

Our study boasts several strengths. Firstly, it pioneers the investigation into the causal link between DM and OM using MR approaches. Notably, it marks the inaugural documentation of the absence of a causal effect of T1DM on OM. Secondly, we employ MR techniques to mitigate potential confounding biases and ensure reliable causal inferences. Thirdly, our use of GWAS data primarily from European ancestry populations minimizes population stratification bias. all outcomes underwent rigorous validation through various sensitivity analyses, including inverse-variance weighted (IVW), MR-Egger, MR-PRESSO, leave-one-out analysis, and MVMR, with multiple testing corrections applied. Furthermore, consistent results across different datasets and meta-analysis underscored the robustness of our findings.

Our study has limitations affecting generalizability and interpretation. Focusing on a single ethnic group restricts broader applicability<sup>34</sup>. Replicating in diverse cohorts is necessary. Reliance on summary statistics from GWAS may introduce misclassification bias. Additionally, while benefiting from large-scale data, our sample size may be insufficient to detect small effect sizes or rare variants. Potential pleiotropy in Mendelian randomization analysis and residual confounding remains concerns, despite sensitivity analyses.

In conclusion, our study offers compelling evidence of a significant causal relationship between genetically determined T2DM and heightened risk of OM, while T1DM shows no causal effects. Additionally, our findings highlight the role of T2DM in mediating the association between RA and OM. These insights hold promise for improving clinical outcomes among diabetic individuals and those at risk of OM.

#### Acknowledgments

We want to acknowledge the participants and investigators of the FinnGen study, UK Biobank, and other GWASs included in this study. Without the dedication of these organizations and their members, this article would have been difficult to complete.

## 1 Funding

6

9

- We thank the Jilin Province Science and Technology Development Grant (grant
- 3 Nos. 20210101452JC and YDZJ202301ZYTS096) for funding this study.

#### 4 Conflict of Interest

5 The authors declare that they have no conflicts of interest.

## Data Availability Statement

All data generated or analyzed during this study are included in this article and its supplementary information files.

## **Ethics Statement**

Not applicable

Author Contributions: L.T. conceived the project, designed the study and

12 revised the manuscript.; YH.L. wrote the manuscript; CY.Z. collected data from the

public database; L.T.,YH.L. and LM.Y. performed the study, and all authors reviewed

14 the manuscript.

# 15 Competing interests

The authors declare no competing interests.

## 17 Consent for Publication

Not applicable

# 19 **Abbreviations**

- T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; OM,
- 21 osteomyelitis; IVW: Inverse variance weighted; IVs: Instrumental variables; SNPs:
- 22 Single Nucleotide Polymorphisms; UVMR, Univariable MR; MVMR: Multivariable
- 23 MR; OR: Odds ratio; CI, confidence interval; GWAS: Genome-Wide Association
- 24 Study; UKBB, United Kingdom Biobank

25

### 26 References

- 27 1. Kremers, H. M. et al. Trends in the epidemiology of osteomyelitis: a
- 28 population-based study, 1969 to 2009. *J. Bone Joint Surg. Am.* **97**, 837–845 (2015).
- 29 2. Lew, D. P. & Waldvogel, F. A. Osteomyelitis. Lancet Lond. Engl. 364, 369–379
- 30 (2004).
- 31 3. Saeedi, P. et al. Global and regional diabetes prevalence estimates for 2019 and
- 32 projections for 2030 and 2045: Results from the International Diabetes Federation
- Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107843 (2019).
- 4. Banday, M. Z., Sameer, A. S. & Nissar, S. Pathophysiology of diabetes: An
- 35 overview. Avicenna J. Med. 10, 174–188 (2020).
- 36 5. Al-Mayahi, M. et al. Associations of diabetes mellitus with orthopaedic infections.
- 37 Infect. Dis. Lond. Engl. 48, 70–73 (2016).
- 38 6. Peng, J. et al. Epidemiological, Clinical and Microbiological Characteristics of
- 39 Patients with Post-Traumatic Osteomyelitis of Limb Fractures in Southwest China: A
- 40 Hospital-Based Study. *J. Bone Jt. Infect.* **2**, 149–153 (2017).

- 1 7. Jha, Y. & Chaudhary, K. Diagnosis and Treatment Modalities for Osteomyelitis.
- 2 *Cureus* **14**, e30713.
- 8. Al-Ahaideb, A. Septic arthritis in patients with rheumatoid arthritis. *J. Orthop.*
- 4 Surg. 3, 33 (2008).
- 5 9. Di Muzio, C., Cipriani, P. & Ruscitti, P. Rheumatoid Arthritis Treatment Options
- 6 and Type 2 Diabetes: Unravelling the Association. BioDrugs Clin. Immunother.
- 7 Biopharm. Gene Ther. **36**, 673–685 (2022).
- 8 10. Z, T., J, M., A, V., H, C. & Ah, H. The relationship between rheumatoid arthritis
- 9 and diabetes mellitus: a systematic review and meta-analysis. Cardiovasc. Endocrinol.
- 10 Metab. 10, (2021).
- 11 11. Sekula, P., Del Greco M, F., Pattaro, C. & Köttgen, A. Mendelian Randomization
- as an Approach to Assess Causality Using Observational Data. J. Am. Soc. Nephrol.
- 13 JASN 27, 3253–3265 (2016).
- 14 12. Skrivankova, V. W. et al. Strengthening the reporting of observational studies in
- 15 epidemiology using mendelian randomisation (STROBE-MR): explanation and
- 16 elaboration. *The BMJ* **375**, n2233 (2021).
- 17 13. Onengut-Gumuscu, S. et al. Fine mapping of type 1 diabetes susceptibility loci
- and evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat.*
- 19 Genet. 47, 381–386 (2015).
- 20 14. Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped
- 21 isolated population. *Nature* **613**, 508–518 (2023).
- 22 15. Xue, A. et al. Genome-wide association analyses identify 143 risk variants and
- putative regulatory mechanisms for type 2 diabetes. *Nat. Commun.* **9**, 2941 (2018).
- 24 16. Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. Nat.
- 25 Genet. **53**, 840–860 (2021).
- 26 17. Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for
- 27 rheumatoid arthritis. *Nat. Genet.* **44**, 1336–1340 (2012).
- 28 18. Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human
- 29 genotype-phenotype associations. *Bioinforma. Oxf. Engl.* **35**, 4851–4853 (2019).
- 30 19. Burgess, S. et al. Guidelines for performing Mendelian randomization
- investigations: update for summer 2023. Wellcome Open Res. 4, 186 (2023).
- 32 20. Carlsson, S., Ahlbom, A., Lichtenstein, P. & Andersson, T. Shared genetic
- influence of BMI, physical activity and type 2 diabetes: a twin study. Diabetologia 56,
- 34 1031–1035 (2013).
- 35 21. Mendelian randomization analysis with multiple genetic variants using
- 36 summarized data PubMed. https://pubmed.ncbi.nlm.nih.gov/24114802/.
- 37 22. Hemani, G. et al. The MR-Base platform supports systematic causal inference
- across the human phenome. *eLife* **7**, e34408.
- 39 23. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for
- 40 performing Mendelian randomization analyses using summarized data. Int. J.

- 1 Epidemiol. **46**, 1734–1739 (2017).
- 2 24. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread
- 3 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
- 4 between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).
- 5 25. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent
- 6 Estimation in Mendelian Randomization with Some Invalid Instruments Using a
- Weighted Median Estimator. Genet. Epidemiol. 40, 304–314 (2016).
- 8 26. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian Randomization
- 9 Analysis With Multiple Genetic Variants Using Summarized Data. *Genet. Epidemiol.*
- 10 **37**, 658–665 (2013).
- 11 27. Brown, N. L. et al. Bioburden after Staphylococcus aureus inoculation in type 1
- diabetic rats undergoing internal fixation. Plast. Reconstr. Surg. 134, 412e–419e
- 13 (2014).
- 14 28. Moschovi, M. et al. Subacute vertebral osteomyelitis in a child with diabetes
- mellitus associated with Fusarium. Pediatr. Int. Off. J. Jpn. Pediatr. Soc. 46, 740–742
- 16 (2004).
- 17 29. Caruso, P. et al. When amputation is not the end of the challenge: A successful
- 18 therapy for osteomyelitis and soft tissue infection in a patient with type  $\square$  1 diabetes. J.
- 19 *Diabetes Investig.* **13**, 209–212 (2022).
- 20 30. Magliano, D. J. et al. Excess Risk of Dying From Infectious Causes in Those
- 21 With Type 1 and Type 2 Diabetes. *Diabetes Care* **38**, 1274–1280 (2015).
- 22 31. Sanderson, E. et al. Mendelian randomization. Nat. Rev. Methods Primer 2, 1–21
- 23 (2022).

- 24 32. Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 Diabetes and
- 25 its Impact on the Immune System. *Curr. Diabetes Rev.* **16**, 442–449 (2020).
- 26 33. Daryabor, G., Atashzar, M. R., Kabelitz, D., Meri, S. & Kalantar, K. The Effects
- of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Front.
- 28 *Immunol.* **11**, 1582 (2020).
- 29 34. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in
- 30 two ☐ sample Mendelian randomization. *Genet. Epidemiol.* **40**, 597 (2016).

## 32 Figure Legends

- 33 Figure 1. Flowchart of the study design. GWAS, genome-wide association studies;
- 34 T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; RA, rheumatoid
- 35 arthritis; OM, osteomyelitis; UVMR, Univariable MR; MVMR, multivariable
- 36 mendelian randomization; BMI, body mass index; UKBB, United Kingdom Biobank;
- 37 IVs, instrument variables.
- 38 **Figure 2.** Genetically predicted type 1 diabetes and its complications: associations
- 39 with osteomyelitis. T1DM, type 1 diabetes mellitus; OM, osteomyelitis; UVMR,
- 40 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,

- 1 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
- 2 Weighted; H, Heterogeneity; P, Pleiotropy. p-values (IVW) □<□0.05 was considered
- 3 suggested different. The Bonferroni-corrected results of the p-values (IVW) in each
- 4 group remained consistent with the uncorrected results.
- 5 **Figure 3.** Genetically predicted type 2 diabetes and its complications: associations
- 6 with osteomyelitis. T2DM, type 2 diabetes mellitus; OM, osteomyelitis; UVMR,
- 7 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,
- 8 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
- 9 Weighted; H, Heterogeneity; P, Pleiotropy. The IVW p-value (<□0.05) was
- 10 considered a statistically suggested difference. IVW p-values below the
- 11 Bonferroni-corrected threshold were considered statistically significant.